Dr Sunil Kumar Nanda, Bharathy N, Dr Lopamudra Ray

Slides:

Advertisements

Similar presentations

A Natural Healthcare Company Pharmanex, Inc. Selected by Nature... Proven by Science.

Advertisements

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.

DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.

#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.

© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without.

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

Circulating Long-Chain ω-3 Fatty Acids and Incidence of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study Funded by: National Institutes.

The association between serum CRP, total cholesterol, triglycerides and coronary artery disease Beata Virginas, Timea Gal.

TECHNOLOGY IN THE MEDICAL FIELD: FOCUSING ON CARDIOVASCULAR DISEASE Lea Anne Cape Dr. Guenzel ENC March 26, 2014.

Lab 6 TC, LDL-C, HDL-C, and TG T.A. Bahiya Osrah

Cholesterol-lowering effects of a stanol- ester containing low-fat margarine used in conjunction with a strict lipid-lowering diet Andersson A et al. Eur.

10 health tests must for men. Men, in particular, are prone to a few diseases. They need to be more concern about these diseases well in time and get.

1 A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547–1554,

Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 2.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Noncommunicable Diseases Surveillance in Egypt

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

The Plasma Concentrations of Atorvastatin and its Active Metabolites in Relation to the Dose in Stable Coronary Artery Disease Patients at a Tertiary Referral.

Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:

M.Sc. in Pharmacy/Clinical Laboratory Sciences

Adiponectin Correlation With Plasma Lipoprotein Subclasses Determined By NMR And With The Risk Of Venous Thrombosis. Fernández JA, Deguchi H, Pecheniuk.

M.Sc. in Pharmacy/Clinical Laboratory Sciences

Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic.

Six sigma matrix-total

Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS

M.Sc. in Pharmacy/Clinical Laboratory Sciences

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

“REGISTRATION COMORBIDITY IN PATIENTS WITH SARCOIDOSIS AND PROGNOSTIC IMPLICATIONS, DATA COLLECTION MODEL ON A SPANISH REGIONAL HOSPITAL.” S. Martín Guillén(1)

Dr. Syed Waleem Pasha Assistant Professor Yenepoya Medical College

Elevated Circulating Levels of Inflammatory Markers in

Fig. 1. Serum total cholesterol (A), LDL cholesterol (B), triglyceride (C) and HDL cholesterol level (D) according to HBsAg status in age group. Total.

Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study M. Lazo, Y. Chen, J.W. McEvoy, C. Ndumele, S. Konety,

Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,

ASSOCIATION OF CLINICAL AND BIOCHEMICAL FACTORS WITH SERUM TESTOSTERONE LEVELS IN TYPE 2 DIABETIC MALES Ravi Kumar Meena, Debasish Chaudhury, Amita.

Copyright © 2007 American Medical Association. All rights reserved.

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

AIM HIGH Niacin plus Statin to prevent vascular events

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Classification of total cholesterol levels

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Oxford Niacin Trial.

The ASSERT Study.

The Chemical Differences Between EPA and DHA.

The percentage of subjects with de novo development of renal function impairment (GFR

Comparison of lipid profile and glycosylated hemoglobin levels among HIV-infected and non-HIV-infected individuals in Lesotho: a community-based cross-sectional.

Type 2 diabetes: Overlap of clinical conditions

Section 7: Aggressive vs moderate approach to lipid lowering

Description of studies for pooled analyses

Dr Stephanie Jones, Dr Amal Khanolkar, Dr Krystyna Matyka,

Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.

The prevalence of Recurrent Stroke and TIA and the related factors

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

An example of the Lancet

Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.

Goals & Guidelines A summary of international guidelines for CHD

Baseline Characteristics of the Subjects*

Cardiovascular Disease in Women Module III: Risk Assessment Tool

Disposition of Patients in the Atherogenic Dyslipidemia Study

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

PROSPER: trial design

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Adjusted relative risk Adjusted odds ratio

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

III. Treating dyslipidemias

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Dr Sunil Kumar Nanda, Bharathy N, Dr Lopamudra Ray Title : Establishment of reference ranges for Lipid profile in puducherry Dr Sunil Kumar Nanda, Bharathy N, Dr Lopamudra Ray

Background IFCC recommends each laboratory to set its own reference ranges for the parameters. In India, most of the laboratories use reference ranges from the kit literature of the manufacturers which are generally based on Western population. The western reference ranges do not match with Indian population for many parameters like lipid profile

Since lipid profile values have direct relationship with development of coronary artery disease, it becomes much more important to follow a reference range which is applicable for the local population. There are very few studies done to establish the reference ranges for lipid profile in Puducherry. Hence this study was taken up.

Aims and Objectives : To establish reference ranges for Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides in Puducherry

Materials and methods The study was a retrospective study. 260 fasting samples of healthy individuals between the age group of 20 to 70 years were analyzed for Total cholesterol, HDL cholesterol, LDL Cholesterol and Triglycerides.

Inclusion criteria Healthy individuals who visited our hospital for master health check up were included in the study

Exclusion criteria 1. Subjects not fasting for 12 hrs 2. Subjects taking lipid lowering drugs 3. Diabetes Mellitus 4. Dyslipidemia 5. Smoking 6. Alcoholics 7.Pregnancy

Methods Total cholesterol : Cholesterol oxidase method HDL Cholesterol : Direct HDL method Triglycerides : Enzymatic colorimetric LDL Cholesterol : Direct LDL method The above mentioned parameters were measured in cobas integra 400 plus We participated in Biorad eqas and CMC eqas

Results and observations Sl No Parameter Mean + SD (mg/dl) 1 Total Cholesterol 190+47 2 HDL Cholesterol 41+10 3 LDL Cholesterol 137+73 4 Triglycerides 133+45

Discussion SL No Parameter Present study Kaur V et al (Punjab) Das M et al (Guwahati) Median Durgawale P et al (Maharashtra) 1 T.Cholesterol 190+47 182.2 ± 33.9 170 (93-263) 165.7±30.2 2 HDL Cholesterol 41+10 44.1 ± 6.8 40 (23-73) 44.86±10.68 3 LDL Cholesterol 137+73 113.9 ± 32.0 103 (40-173) 101.66±29.8 4 Triglycerides 133+45 122.4 ± 33.4 110 (40-256) 88.36±31.2

Conclusion Our results shows higher difference in reference ranges for LDL cholesterol when compared to LDL values of other regions of India We recommend studies to be done on reference ranges of lipid profile with a larger sample size